98818-41-8

Basic information

• Product Name: (3R,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one
• Synonyms: (3R,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one
• CAS NO: 98818-41-8
• Molecular Weight: 395.499
• Mol File: 98818-41-8.mol
• Article Data: 21

Chemical Properties

• CAS DataBase Reference: (3R,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one(98818-41-8)
• EPA Substance Registry System: (3R,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one(98818-41-8)

Safety Data

• Hazardous Substances Data: 98818-41-8(Hazardous Substances Data)

Upstream product

• 133333-27-4 tert-butyl (1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate 
• 620-05-3 iodomethylbenzene 
• 98818-42-9 (3S,5S)-3-benzyl-5-{(1S)-1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}dihydrofuran-2-(3H)-one 
• 100-39-0 benzyl bromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 137007-28-4 (S)-2-Methoxy-5-(R)-oxiranyl-tetrahydro-furan 
• 61845-17-8 methyl D-2,3-dideoxyglucofuranoside 
• 98818-43-0 (2R,4R,5S)-2-Benzyl-5-(tert-butoxycarbonyl)amino-4-hydroxy-6-phenylhexanoic acid 
• 7226-23-5 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
• 14131-84-1 2,3:5,6-di-O-isopropylidene-α-D-mannofuranose 
• 137038-63-2 deux références: JFP452-1 et JFP456b 
• 137007-30-8 (R)-1-((S)-5-Methoxy-tetrahydro-furan-2-yl)-2-phenyl-ethanol 
• 137007-25-1 (R)-4-((S)-5-Methoxy-2,5-dihydro-furan-2-yl)-2,2-dimethyl-[1,3]dioxolane 
• 68144-11-6 1,4-anhydro-2-deoxy-5,6-O-isopropylidene-D-arabinohex-1-enitol 

Downstream Products

• 161916-90-1 (3R,5S)-5-((S)-1-Amino-2-phenyl-ethyl)-3-benzyl-dihydro-furan-2-one 
• 126410-59-1 C₃₉H₅₄N₂O₆Si 
• 126409-25-4 (2R,4S,5S)-N,2-dibenzyl-5-[(tert-butoxycarbonyl)amino]-4-hydroxy-6-phenylhexanamide 
• 98818-74-7 L-364,505 
• 132565-30-1 ((S)-1-{(1S,2S,4R)-1-Benzyl-4-[(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-3-methyl-butylcarbamoyl]-2-hydroxy-5-phenyl-pentylcarbamoyl}-2-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 126410-69-3 [(1S,2S,4R)-4-{(S)-1-[(1H-Benzoimidazol-2-ylmethyl)-carbamoyl]-2-methyl-butylcarbamoyl}-1-benzyl-2-(tert-butyl-dimethyl-silanyloxy)-5-phenyl-pentyl]-carbamic acid tert-butyl ester 
• 126409-81-2 N'-(2-benzimidazolylmethyl)-N-<5(S)-<(tert-butoxycarbonyl)amino>-4(S)-hydroxy-6-phenyl-2(R)-(phenylmethyl)hexanoyl>isoleucine amide 
• 98818-75-8 [(1S,2S,4R)-1-Benzyl-4-((S)-1-benzylcarbamoyl-3-methyl-butylcarbamoyl)-2-(tert-butyl-dimethyl-silanyloxy)-5-phenyl-pentyl]-carbamic acid tert-butyl ester 
• 129252-98-8 [(1S,2S,4R)-1-Benzyl-4-((S)-1-benzylcarbamoyl-2-methyl-butylcarbamoyl)-2-(tert-butyl-dimethyl-silanyloxy)-5-phenyl-pentyl]-carbamic acid tert-butyl ester 
• 132565-31-2 [(1S,2S,4R)-1-Benzyl-2-hydroxy-4-((S)-3-methyl-1-phenethylcarbamoyl-butylcarbamoyl)-5-phenyl-pentyl]-carbamic acid tert-butyl ester 
• 98818-68-9 [(1S,2S,4R)-1-Benzyl-4-((S)-1-benzylcarbamoyl-3-methyl-butylcarbamoyl)-2-hydroxy-5-phenyl-pentyl]-carbamic acid tert-butyl ester 
• 126409-47-0 [(1S,2S,4R)-1-Benzyl-4-((S)-1-benzylcarbamoyl-2-methyl-butylcarbamoyl)-2-hydroxy-5-phenyl-pentyl]-carbamic acid tert-butyl ester 
• 126409-66-3 {(1S,2S,4R)-1-Benzyl-4-[(S)-1-(2,3-dihydroxy-propylcarbamoyl)-2-methyl-butylcarbamoyl]-2-hydroxy-5-phenyl-pentyl}-carbamic acid tert-butyl ester 
• 129252-92-2 (2R,4S,5S)-5-Amino-2-benzyl-4-hydroxy-6-phenyl-hexanoic acid [(S)-1-((S)-1-carbamoyl-2-phenyl-ethylcarbamoyl)-3-methyl-butyl]-amide 

Relevant articles and documents

Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application

The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1-22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe-Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing a heterocyclic 6-methoxy-3-pyridinyl or a 6-(dimethylamino)-3-pyridinyl moiety (R3) at the para-position of the P1′ benzyl fragment generated compounds with antiviral potency in the low single digit nanomolar range. Halogenation or alkylation of the metabolic hot spots on the various aromatic rings resulted in PIs with high stability against degradation in human liver microsomes and low plasma clearance in rats. Replacing the chromanolamine moiety (R1) in the P2 protease binding site by a cyclopentanolamine or a cyclohexanolamine derivative provided a series of high clearance PIs (16-22) with EC50s on wild-type HIV-1 in the range of 0.8-1.8 nM. PIs 18 and 22, formulated as nanosuspensions, showed gradual but sustained and complete release from the injection site over two months in rats, and were therefore identified as interesting candidates for a LA injectable drug application for treating HIV/AIDS.

Application of the asymmetric aminohydroxylation reaction for the syntheses of HIV-protease inhibitor, hydroxyethylene dipeptide isostere and γ-amino acid derivative

An enantioselective synthesis of lactone 1, a precursor to the (2R,4S,5S) hydroxyethylene dipeptide isostere and amino acid AHPPA 2 has been accomplished from the common intermediate 5 employing Sharpless asymmetric aminohydroxylation as the key step.

Short total synthesis of aspartyl protease inhibitors L-685,434, L-682,679 and L-685,458

Hydroxyethylene dipeptide isosteres L-685,434, L-682,679 and L-685,458 were synthesized in a few steps by a sequence involving an allyltrichlorostannane coupling with an α-aminoaldehyde followed by hydroboration of the corresponding 1,2-syn and 1,2-anti a